SlideShare a Scribd company logo
1 of 24
Download to read offline
August 17, 2017
NOT FOR U.S. AND CANADA AUDIENCE
Afshin Sohrabi, PhD
Principal Scientist, Development Services
Process Solution Services
Rapid Methodologies
for Biosafety Testing
of Biologic Therapies
Microbial Contamination & Production of Biologics
2
Manufacturing of Biologic Drugs
Final
Drug
Product
Research
Cell Line
Production Cell Line
(“Cell Bank”)
Cell engineering, selection
& integration site analysis
Media development,
Raw Materials selection
Chromatography
resin selection, yield
optimization, product
characterization
Formulation
development, stability
testing, fill & finish
“In process”
testing
Bioreactor
Purified Bulk
Drug Substance
Unprocessed
Bulk Product
Upstream processing Downstream processing
Material (Cell, Virus, Raw Material) Characterization Lot Release Testing
• Production of biopharmaceuticals (i.e.,
biologics) typically involves the use of
living cells
• As a consequence, the manufacturing
process and products are prone to
contamination by exogenous
(Adventitious) agents and endogenous
microbial agents (e.g., retroviruses for
rodent cell lines)
3
Historical contamination events for biologics
Why does adventitious agent testing need to be
performed?
Human Products:
• Contaminated with blood borne viruses:
HIV, HBV, HCV, B19 parvovirus
• vCJD (whole blood)
Excipients:
 Yellow fever vaccine formulated with
human serum albumin that was
contaminated with HBV
 Recent PCV (porcine circovirus) DNA
contamination in rotavirus vaccines
Cell Lines:
• Rhesus Monkey cells used to produce
polio vaccines contaminated with
SV40
 SV40 now classified as a
human pathogen
• Contamination events in CHO
cells : Reovirus; Epizootic
Hemorrhagic Disease Virus
(EHDV); Minute Virus of Mice
(MMV, a parvovirus); Cache
Valley Virus (Bunyavirus);
Calicivirus
Manufacturing of Generic Biologics
Large Scale Process with multiple handling points prone to contamination
with Adventitious Agents - Testing Points to mitigate risks
4
Current Testing Methodology
In Vitro virus Detection: Cell Culture Based Assay
5
Regulatory Agencies
US Food and Drug Administration (FDA)
 Center for Drugs Evaluation and Research (CDER)
 Center for Biologics Evaluation and Research (CBER)
China
• China Food and Drug Administration (CFDA)
Japan
 Pharmaceuticals and Medical Device Agency (PMDA)
EU
• European Medicines Evaluation Agency (EMA)
 MHRA
Korea
 Ministry of Food and Drug Safety (MFDS)
World Health Organization
Biological Safety Testing is Mandated by Regulatory Agencies Worldwide
5
7
Value of Scalable NRTT
Testing tools are rapidly evolving to better
evaluate and mitigate risk....
Standard PCR  qPCR  Digital PCR
Sanger  Next Generation Sequencing (NGS)
Traditional  Rapid Chemical based Testing
8
A poll will now
occur
10
Once we
accept our
limits,
we go beyond
them.
Albert Einstein
Regulatory Documents in Support of Molecular Based Testing
Excerpt for Page 28 of FDA Guidance
11
Ph. Eur. Chapter 5.2.14: Substitution of in vivo method(s) by in vitro methods for the quality of
vaccines (Pharmeuropa 28.2; April 2106)
“…Novel sensitive molecular techniques with broad detection capabilities are available, including deep
sequencing or high throughput sequencing methods, degenerate PCR for whole virus families or random
priming methods…”
Regulations are not Opposed to Alternative Methods
12
More Regulatory Documents in Support of Molecular Based Testing
Continuing contamination events
Discovery of new non-culturable viruses
Development of new, rapid methods to detect contaminants
 How and when to use, interpreting results
 PCRs, rapid microbiology methods, Massively Parallel Sequencing
Use of new cell substrates
 New transformed cells for vaccine production, insect cell lines
New product types
 Advanced therapies: gene therapy, cell therapy including stem cells, tissue engineering
 Biosimilar products
New production processes
New endpoints for clinical trials
 Biomarkers, pharmacogenomic analysis
Why Seek Alternative Testing Methods
Challenges Facing Industry and Regulators
13
Scientific and Regulatory Drivers for Innovation in the Biological Safety Testing
14
Challenges in cGMP Testing for Emerging Viruses
GMP Raw Materials: Viral Contaminants in Bovine Serum and Porcine Trypsin
1. The study by Dr. Carol Marcus-Sekura, James C. Richardson, Rebecca K. Harston, Nandini Sane
and Rebecca L. Sheets at BASI, ABSL & NIH (2011): Evaluation of the Human Range of Bovine
and Porcine Viruses that may Contaminate Bovine Serum and Porcine Trypsin Used in the
Manufacture of Biological Products, in Biologicals, 29 (6): 359-369
2. The authors pointed out that the current 9CFR (USDA) tests for bovine serum and porcine
trypsin were not sufficient, there is risk in missing viruses within virus families (such as new
viruses discovered using molecular methods).
3. Alternative methodologies should be evaluated. They recommended to incorporate virus-family
testing for raw materials:
1) Virus family-specific PCR assays
2) Better sensitivity
3) Direct detection of non-culturable viruses
A poll will now
occur
16
Design Degenerate PCR Based Assay for Detection of Members of virus families
For Detection and Characterization of unknown virus in sample
Degenerate & Multiplex Primers
for families of DNA viruses
(Ref. Carol Marcus-Sekura et
al. 2011)
Degenerate & Multiplex Primers for families of RNA
viruses (Ref. Carol Marcus-Sekura et al. 2011)
Degenerate PCR Based Assay
3 Step Process: Sample Extraction, PCR Amplification, Detection
17
Automated Large
Volume (1-10ml)
magnetic-Bead
Based Extraction
Degenerate Primers target
virus families and
multiplexing approach to
increase throughput
The assay is an integration
of detection (PCR) and
identification (via amplicon
size/sequencing analysis)
18
Single Target Detection Scheme
1 10 100 10000# of
Particles
1e6 CHO
Cells
DNA
Extraction
Output
Result
Extraction, 260/280 OD Reading
Determine genomic copies (GC) using ddPCR
MMV
Virus
Stock
Test Sensitivity and Specificity of Methodology:
1. Add MMV to CHO Cell in a single reaction
2. Extract genomic material from MMV & CHO Mix
3. Perform PCR
4. Detect and size the single Amplicon by Capillary End Point
Analysis
Mouse Minute Virus (MMV):
• Member of Parvovirus family
• Source of several bioreactor contamination events in industry
Detection of Mouse Minute Virus (MMV) in CHO Cell Matrix
Assay Sensitivity and Specificity equivalent to Compendial Method
MMV Particle
Spike in CHO
Cells
Detected
0 No
1 No
10 Yes
100 Yes
Input-GC Culture-PFU
1000 GC 3.091
100 GC 0.309
10 GC 0.031
Ratio (pfu/GC)
Polymer Capillary
End Point Analysis
Fluorescent Labeled
Based PCR
19
Detection of 44 Individual Parvoviruses Targets represented by 13
Peaks
HPV –B19
HPV-4
MMV-Group
PPV-1
BPV-1
HBoV
BPV-3
PBoV
BHoko
ChiPV
PPV-456
PPV-23HOKO
BPV-2
MMV
Mouse Parvovirus 4a &4b
Hamster Parvovirus
Rat Parvovirus
Bat Parvovirus
Kilham rat virus
Feline panleukopenia virus
Tumor virus -X
Canine Parvovirus
Mink enteritis virus
Multiple Target Detection Scheme
44 Targets + Degenerate
Multiplex Primer Mix
Polymer Capillary
End Point Analysis
Assay Approach
1. Mix 44 Individual ParvoV Targets in one reaction
2. Perform PCR
3. Detect and size the Multiple Amplicons by Capillary End Point
Analysis
Multiplex Assay Panel Covers:
• Targets that have been previously identified
• Ability to detect targets that have not been formally identified – e.g., new variants
Target Detected
BPV-3 Yes
HPV-4 Yes
MMV Group
(All reported 19
MMV Strains)
Yes
PPV-1 Yes
HBoV
Yes
HPV-B19
Yes
PBoV
Yes
BHoKo
Yes
ChiP
Yes
PPV-456
Yes
PPV-23HOKO
Yes
BPV-1
Yes
BPV-2 YesFluorescent Labeled
Based PCR
20
Testing Bovine Serum Albumin (BSA) using the Parvovirus Panel
Raw Material Case Study
Why Test BSA?
Used to Stabilize PCR
formulations
How was it tested?
Directly add 2l BSA to
PCR Mix
Outcome?
A peak/band in BSA
correlating to BPV-3
Detection and Identification of Viral Sequence (Bovine Parvovirus 3) in commercially available BSA
Peak confirmation
Sanger sequencing confirms
presence of BPV-3 DNA with
99% identity
BPV-3
ParvoV Panel Assay
Multiplex primers: Generate Specific BPV-3 Signal
Target Detected
BPV-3 No
HPV-4 No
MMV Group
(All reported 19 MMV
Strains)
No
PPV-1 No
HBoV
No
HPV-B19 No
PBoV
No
BHoKo No
ChiP No
PPV-456 No
PPV-23HOKO
No
BPV-1 No
BPV-2 No
BPV-3 Yes
21
Raw Material Case Study
MMV Spiked Unprocessed Bulk Bioreactor Material Analyzed
Unprocessed Bulk
1ml of
Unprocessed
Bulk
1TCID50 MMV Spike
1ml of
Unprocessed
Bulk
Spike
1X PBS
Sample
Purification
Sample
Purification
Bioreactor
Target Detected
BPV-3 No
HPV-4 No
MMV Group
(All reported 19 MMV
Strains)
Yes
PPV-1 No
HBoV
No
HPV-B19 No
PBoV
No
BHoKo No
ChiP No
PPV-456 No
PPV-23HOKO
No
BPV-1 No
BPV-2 No
BPV-3 No
Target Detected
BPV-3 No
HPV-4 No
MMV Group
(All reported 19 MMV
Strains)
No
PPV-1 No
HBoV
No
HPV-B19 No
PBoV
No
BHoKo No
ChiP No
PPV-456 No
PPV-23HOKO
No
BPV-1 No
BPV-2 No
BPV-3 No
Results
Results
• High sensitivity and specificity for detection of Adventitious Agents
• Faster molecular test results would provide better control over the manufacturing process
• Broad spectrum helps further reduce risk
• Can detect both culturable and non-culturable viruses
• Earlier results = earlier release of product: months to days/hours: inventory, space, facility utilization
• Newer biologics have short shelf life and are not amenable to cryopreservation storage
Benefits of degenerate primer methodology
Advantages:
22
Disadvantages:
• Molecular methods are not able to distinguish between infectious virus vs. “free” DNA/RNA
 This risk can be mitigated by screening the starting material upfront. If a virus persists and
contaminates your product, then risk has been mitigated by early detection of the virus.
Team Acknowledgments
Quanyi (Charlie) Li, PhD
Teng Vang, MS
Audrey Chang, PhD
Reginald Clayton, PhD
Adam Inche, PhD
Colette Cote, PhD
Martin Wisher, PhD
Karin Heffner, PM
23
A poll will now
occur
Questions?
25
Dr Afshin Sohrabi
BioReliance,
Rockville, MD
afshin.sohrabi@sial.com

More Related Content

What's hot

Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
 
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapyProcess Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapyMerck Life Sciences
 
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsBreaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences
 
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Merck Life Sciences
 
QBD for Downstream Virus Filtration
QBD for Downstream Virus FiltrationQBD for Downstream Virus Filtration
QBD for Downstream Virus FiltrationMilliporeSigma
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMilliporeSigma
 
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisSee the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisMilliporeSigma
 
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...MilliporeSigma
 
Learn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigmaLearn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigmaMilliporeSigma
 
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Merck Life Sciences
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMerck Life Sciences
 
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Merck Life Sciences
 
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...MilliporeSigma
 
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentWebinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentMilliporeSigma
 

What's hot (14)

Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
 
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapyProcess Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
 
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsBreaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
 
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
 
QBD for Downstream Virus Filtration
QBD for Downstream Virus FiltrationQBD for Downstream Virus Filtration
QBD for Downstream Virus Filtration
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisSee the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
 
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
 
Learn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigmaLearn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigma
 
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
 
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
 
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentWebinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
 

Viewers also liked

Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...
Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...
Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...Merck Life Sciences
 
Venture Capital Funding: An Insider’s View
Venture Capital Funding: An Insider’s ViewVenture Capital Funding: An Insider’s View
Venture Capital Funding: An Insider’s ViewMerck Life Sciences
 
Managing Process Scale-up and Tech Transfer 
Managing Process Scale-up and Tech Transfer Managing Process Scale-up and Tech Transfer 
Managing Process Scale-up and Tech Transfer Merck Life Sciences
 
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...Merck Life Sciences
 
Integrity Test Troubleshooting – Beyond Rewet and Retest
Integrity Test Troubleshooting – Beyond Rewet and RetestIntegrity Test Troubleshooting – Beyond Rewet and Retest
Integrity Test Troubleshooting – Beyond Rewet and RetestMerck Life Sciences
 
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...Merck Life Sciences
 
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...Merck Life Sciences
 
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...Merck Life Sciences
 
The Comprehensive Guide to Genotoxicity Assessment
The Comprehensive Guide to Genotoxicity AssessmentThe Comprehensive Guide to Genotoxicity Assessment
The Comprehensive Guide to Genotoxicity AssessmentMerck Life Sciences
 
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and InnovationsSerum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and InnovationsMerck Life Sciences
 
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Merck Life Sciences
 
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Merck Life Sciences
 
Cells Powerpoint Presentation
Cells Powerpoint PresentationCells Powerpoint Presentation
Cells Powerpoint Presentationcprizel
 

Viewers also liked (13)

Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...
Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...
Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...
 
Venture Capital Funding: An Insider’s View
Venture Capital Funding: An Insider’s ViewVenture Capital Funding: An Insider’s View
Venture Capital Funding: An Insider’s View
 
Managing Process Scale-up and Tech Transfer 
Managing Process Scale-up and Tech Transfer Managing Process Scale-up and Tech Transfer 
Managing Process Scale-up and Tech Transfer 
 
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...
 
Integrity Test Troubleshooting – Beyond Rewet and Retest
Integrity Test Troubleshooting – Beyond Rewet and RetestIntegrity Test Troubleshooting – Beyond Rewet and Retest
Integrity Test Troubleshooting – Beyond Rewet and Retest
 
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
 
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...
 
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...
 
The Comprehensive Guide to Genotoxicity Assessment
The Comprehensive Guide to Genotoxicity AssessmentThe Comprehensive Guide to Genotoxicity Assessment
The Comprehensive Guide to Genotoxicity Assessment
 
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and InnovationsSerum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
 
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
 
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
 
Cells Powerpoint Presentation
Cells Powerpoint PresentationCells Powerpoint Presentation
Cells Powerpoint Presentation
 

Similar to Rapid Methodologies for Biosafety Testing of Biologic Therapeutics

Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngMilliporeSigma
 
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngMerck Life Sciences
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?MilliporeSigma
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
 
Does your cell line have a secret? Avoid surprises with characterization
Does your cell line have a secret? Avoid surprises with characterizationDoes your cell line have a secret? Avoid surprises with characterization
Does your cell line have a secret? Avoid surprises with characterizationMerck Life Sciences
 
Does your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterizationDoes your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterizationMilliporeSigma
 
Biosafety Testing Solutions for Cell & Gene Therapy
Biosafety Testing Solutions for Cell & Gene TherapyBiosafety Testing Solutions for Cell & Gene Therapy
Biosafety Testing Solutions for Cell & Gene TherapyMerck Life Sciences
 
Vaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed CharacterizationVaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed CharacterizationMerck Life Sciences
 
Vaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed CharacterizationVaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed CharacterizationMilliporeSigma
 
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)HadiaNaz1
 
Production and purification of Viral vectors for gene and cell therapy appli...
Production and purification of  Viral vectors for gene and cell therapy appli...Production and purification of  Viral vectors for gene and cell therapy appli...
Production and purification of Viral vectors for gene and cell therapy appli...Dr. Priyabrata Pattnaik
 
Microbiological identification
Microbiological identification Microbiological identification
Microbiological identification Alma Tammour
 
Fenicia_2011_IJFM_145_S152-S157
Fenicia_2011_IJFM_145_S152-S157Fenicia_2011_IJFM_145_S152-S157
Fenicia_2011_IJFM_145_S152-S157Raditijo Hamidjaja
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyMerck Life Sciences
 
Accelerating Usp
Accelerating UspAccelerating Usp
Accelerating UspSMEbiotech
 
Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development OSUCCC - James
 
Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013Elsa von Licy
 

Similar to Rapid Methodologies for Biosafety Testing of Biologic Therapeutics (20)

Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
 
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?
 
Does your cell line have a secret? Avoid surprises with characterization
Does your cell line have a secret? Avoid surprises with characterizationDoes your cell line have a secret? Avoid surprises with characterization
Does your cell line have a secret? Avoid surprises with characterization
 
Does your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterizationDoes your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterization
 
Biosafety Testing Solutions for Cell & Gene Therapy
Biosafety Testing Solutions for Cell & Gene TherapyBiosafety Testing Solutions for Cell & Gene Therapy
Biosafety Testing Solutions for Cell & Gene Therapy
 
Vaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed CharacterizationVaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed Characterization
 
Vaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed CharacterizationVaccine Cell Bank and Virus Seed Characterization
Vaccine Cell Bank and Virus Seed Characterization
 
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
 
Production and purification of Viral vectors for gene and cell therapy appli...
Production and purification of  Viral vectors for gene and cell therapy appli...Production and purification of  Viral vectors for gene and cell therapy appli...
Production and purification of Viral vectors for gene and cell therapy appli...
 
Microbiological identification
Microbiological identification Microbiological identification
Microbiological identification
 
Fenicia_2011_IJFM_145_S152-S157
Fenicia_2011_IJFM_145_S152-S157Fenicia_2011_IJFM_145_S152-S157
Fenicia_2011_IJFM_145_S152-S157
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
 
Accelerating Usp
Accelerating UspAccelerating Usp
Accelerating Usp
 
Choosing best laboratory practice
Choosing best laboratory practiceChoosing best laboratory practice
Choosing best laboratory practice
 
NDBD
NDBDNDBD
NDBD
 
Thesis
ThesisThesis
Thesis
 
Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development
 
Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013
 

More from Merck Life Sciences

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeMerck Life Sciences
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsMerck Life Sciences
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesMerck Life Sciences
 
Regulatory Considerations for Excipients used in Lipid Nanoparticles
Regulatory Considerations for Excipients used in Lipid NanoparticlesRegulatory Considerations for Excipients used in Lipid Nanoparticles
Regulatory Considerations for Excipients used in Lipid NanoparticlesMerck Life Sciences
 

More from Merck Life Sciences (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 
Regulatory Considerations for Excipients used in Lipid Nanoparticles
Regulatory Considerations for Excipients used in Lipid NanoparticlesRegulatory Considerations for Excipients used in Lipid Nanoparticles
Regulatory Considerations for Excipients used in Lipid Nanoparticles
 

Recently uploaded

Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near MeRussian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Memriyagarg453
 
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetdhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...indiancallgirl4rent
 
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅gragmanisha42
 
VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171Call Girls Service Gurgaon
 
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetNanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetOzhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetErnakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Chandigarh
 
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.ktanvi103
 
VIP Call Girl Sector 32 Noida Just Book Me 9711199171
VIP Call Girl Sector 32 Noida Just Book Me 9711199171VIP Call Girl Sector 32 Noida Just Book Me 9711199171
VIP Call Girl Sector 32 Noida Just Book Me 9711199171Call Girls Service Gurgaon
 
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur RajasthanJaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthanindiancallgirl4rent
 
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...Gfnyt.com
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...Gfnyt.com
 
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near MeVIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Memriyagarg453
 
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Sheetaleventcompany
 
Call Girl Raipur 📲 9999965857 whatsapp live cam sex service available
Call Girl Raipur 📲 9999965857 whatsapp live cam sex service availableCall Girl Raipur 📲 9999965857 whatsapp live cam sex service available
Call Girl Raipur 📲 9999965857 whatsapp live cam sex service availablegragmanisha42
 

Recently uploaded (20)

Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near MeRussian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
 
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetdhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
 
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
 
VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171
 
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
 
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetNanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetOzhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetErnakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
 
9316020077📞Goa Call Girls Numbers, Call Girls Whatsapp Numbers Goa
9316020077📞Goa  Call Girls  Numbers, Call Girls  Whatsapp Numbers Goa9316020077📞Goa  Call Girls  Numbers, Call Girls  Whatsapp Numbers Goa
9316020077📞Goa Call Girls Numbers, Call Girls Whatsapp Numbers Goa
 
VIP Call Girl Sector 32 Noida Just Book Me 9711199171
VIP Call Girl Sector 32 Noida Just Book Me 9711199171VIP Call Girl Sector 32 Noida Just Book Me 9711199171
VIP Call Girl Sector 32 Noida Just Book Me 9711199171
 
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur RajasthanJaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
 
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...
 
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near MeVIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
 
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
 
Call Girl Raipur 📲 9999965857 whatsapp live cam sex service available
Call Girl Raipur 📲 9999965857 whatsapp live cam sex service availableCall Girl Raipur 📲 9999965857 whatsapp live cam sex service available
Call Girl Raipur 📲 9999965857 whatsapp live cam sex service available
 

Rapid Methodologies for Biosafety Testing of Biologic Therapeutics

  • 1. August 17, 2017 NOT FOR U.S. AND CANADA AUDIENCE Afshin Sohrabi, PhD Principal Scientist, Development Services Process Solution Services Rapid Methodologies for Biosafety Testing of Biologic Therapies
  • 2. Microbial Contamination & Production of Biologics 2 Manufacturing of Biologic Drugs Final Drug Product Research Cell Line Production Cell Line (“Cell Bank”) Cell engineering, selection & integration site analysis Media development, Raw Materials selection Chromatography resin selection, yield optimization, product characterization Formulation development, stability testing, fill & finish “In process” testing Bioreactor Purified Bulk Drug Substance Unprocessed Bulk Product Upstream processing Downstream processing Material (Cell, Virus, Raw Material) Characterization Lot Release Testing • Production of biopharmaceuticals (i.e., biologics) typically involves the use of living cells • As a consequence, the manufacturing process and products are prone to contamination by exogenous (Adventitious) agents and endogenous microbial agents (e.g., retroviruses for rodent cell lines)
  • 3. 3 Historical contamination events for biologics Why does adventitious agent testing need to be performed? Human Products: • Contaminated with blood borne viruses: HIV, HBV, HCV, B19 parvovirus • vCJD (whole blood) Excipients:  Yellow fever vaccine formulated with human serum albumin that was contaminated with HBV  Recent PCV (porcine circovirus) DNA contamination in rotavirus vaccines Cell Lines: • Rhesus Monkey cells used to produce polio vaccines contaminated with SV40  SV40 now classified as a human pathogen • Contamination events in CHO cells : Reovirus; Epizootic Hemorrhagic Disease Virus (EHDV); Minute Virus of Mice (MMV, a parvovirus); Cache Valley Virus (Bunyavirus); Calicivirus
  • 4. Manufacturing of Generic Biologics Large Scale Process with multiple handling points prone to contamination with Adventitious Agents - Testing Points to mitigate risks 4 Current Testing Methodology In Vitro virus Detection: Cell Culture Based Assay
  • 5. 5 Regulatory Agencies US Food and Drug Administration (FDA)  Center for Drugs Evaluation and Research (CDER)  Center for Biologics Evaluation and Research (CBER) China • China Food and Drug Administration (CFDA) Japan  Pharmaceuticals and Medical Device Agency (PMDA) EU • European Medicines Evaluation Agency (EMA)  MHRA Korea  Ministry of Food and Drug Safety (MFDS) World Health Organization Biological Safety Testing is Mandated by Regulatory Agencies Worldwide 5
  • 7. Testing tools are rapidly evolving to better evaluate and mitigate risk.... Standard PCR  qPCR  Digital PCR Sanger  Next Generation Sequencing (NGS) Traditional  Rapid Chemical based Testing 8
  • 8. A poll will now occur
  • 9. 10 Once we accept our limits, we go beyond them. Albert Einstein
  • 10. Regulatory Documents in Support of Molecular Based Testing Excerpt for Page 28 of FDA Guidance 11
  • 11. Ph. Eur. Chapter 5.2.14: Substitution of in vivo method(s) by in vitro methods for the quality of vaccines (Pharmeuropa 28.2; April 2106) “…Novel sensitive molecular techniques with broad detection capabilities are available, including deep sequencing or high throughput sequencing methods, degenerate PCR for whole virus families or random priming methods…” Regulations are not Opposed to Alternative Methods 12 More Regulatory Documents in Support of Molecular Based Testing
  • 12. Continuing contamination events Discovery of new non-culturable viruses Development of new, rapid methods to detect contaminants  How and when to use, interpreting results  PCRs, rapid microbiology methods, Massively Parallel Sequencing Use of new cell substrates  New transformed cells for vaccine production, insect cell lines New product types  Advanced therapies: gene therapy, cell therapy including stem cells, tissue engineering  Biosimilar products New production processes New endpoints for clinical trials  Biomarkers, pharmacogenomic analysis Why Seek Alternative Testing Methods Challenges Facing Industry and Regulators 13 Scientific and Regulatory Drivers for Innovation in the Biological Safety Testing
  • 13. 14 Challenges in cGMP Testing for Emerging Viruses GMP Raw Materials: Viral Contaminants in Bovine Serum and Porcine Trypsin 1. The study by Dr. Carol Marcus-Sekura, James C. Richardson, Rebecca K. Harston, Nandini Sane and Rebecca L. Sheets at BASI, ABSL & NIH (2011): Evaluation of the Human Range of Bovine and Porcine Viruses that may Contaminate Bovine Serum and Porcine Trypsin Used in the Manufacture of Biological Products, in Biologicals, 29 (6): 359-369 2. The authors pointed out that the current 9CFR (USDA) tests for bovine serum and porcine trypsin were not sufficient, there is risk in missing viruses within virus families (such as new viruses discovered using molecular methods). 3. Alternative methodologies should be evaluated. They recommended to incorporate virus-family testing for raw materials: 1) Virus family-specific PCR assays 2) Better sensitivity 3) Direct detection of non-culturable viruses
  • 14. A poll will now occur
  • 15. 16 Design Degenerate PCR Based Assay for Detection of Members of virus families For Detection and Characterization of unknown virus in sample Degenerate & Multiplex Primers for families of DNA viruses (Ref. Carol Marcus-Sekura et al. 2011) Degenerate & Multiplex Primers for families of RNA viruses (Ref. Carol Marcus-Sekura et al. 2011)
  • 16. Degenerate PCR Based Assay 3 Step Process: Sample Extraction, PCR Amplification, Detection 17 Automated Large Volume (1-10ml) magnetic-Bead Based Extraction Degenerate Primers target virus families and multiplexing approach to increase throughput The assay is an integration of detection (PCR) and identification (via amplicon size/sequencing analysis)
  • 17. 18 Single Target Detection Scheme 1 10 100 10000# of Particles 1e6 CHO Cells DNA Extraction Output Result Extraction, 260/280 OD Reading Determine genomic copies (GC) using ddPCR MMV Virus Stock Test Sensitivity and Specificity of Methodology: 1. Add MMV to CHO Cell in a single reaction 2. Extract genomic material from MMV & CHO Mix 3. Perform PCR 4. Detect and size the single Amplicon by Capillary End Point Analysis Mouse Minute Virus (MMV): • Member of Parvovirus family • Source of several bioreactor contamination events in industry Detection of Mouse Minute Virus (MMV) in CHO Cell Matrix Assay Sensitivity and Specificity equivalent to Compendial Method MMV Particle Spike in CHO Cells Detected 0 No 1 No 10 Yes 100 Yes Input-GC Culture-PFU 1000 GC 3.091 100 GC 0.309 10 GC 0.031 Ratio (pfu/GC) Polymer Capillary End Point Analysis Fluorescent Labeled Based PCR
  • 18. 19 Detection of 44 Individual Parvoviruses Targets represented by 13 Peaks HPV –B19 HPV-4 MMV-Group PPV-1 BPV-1 HBoV BPV-3 PBoV BHoko ChiPV PPV-456 PPV-23HOKO BPV-2 MMV Mouse Parvovirus 4a &4b Hamster Parvovirus Rat Parvovirus Bat Parvovirus Kilham rat virus Feline panleukopenia virus Tumor virus -X Canine Parvovirus Mink enteritis virus Multiple Target Detection Scheme 44 Targets + Degenerate Multiplex Primer Mix Polymer Capillary End Point Analysis Assay Approach 1. Mix 44 Individual ParvoV Targets in one reaction 2. Perform PCR 3. Detect and size the Multiple Amplicons by Capillary End Point Analysis Multiplex Assay Panel Covers: • Targets that have been previously identified • Ability to detect targets that have not been formally identified – e.g., new variants Target Detected BPV-3 Yes HPV-4 Yes MMV Group (All reported 19 MMV Strains) Yes PPV-1 Yes HBoV Yes HPV-B19 Yes PBoV Yes BHoKo Yes ChiP Yes PPV-456 Yes PPV-23HOKO Yes BPV-1 Yes BPV-2 YesFluorescent Labeled Based PCR
  • 19. 20 Testing Bovine Serum Albumin (BSA) using the Parvovirus Panel Raw Material Case Study Why Test BSA? Used to Stabilize PCR formulations How was it tested? Directly add 2l BSA to PCR Mix Outcome? A peak/band in BSA correlating to BPV-3 Detection and Identification of Viral Sequence (Bovine Parvovirus 3) in commercially available BSA Peak confirmation Sanger sequencing confirms presence of BPV-3 DNA with 99% identity BPV-3 ParvoV Panel Assay Multiplex primers: Generate Specific BPV-3 Signal Target Detected BPV-3 No HPV-4 No MMV Group (All reported 19 MMV Strains) No PPV-1 No HBoV No HPV-B19 No PBoV No BHoKo No ChiP No PPV-456 No PPV-23HOKO No BPV-1 No BPV-2 No BPV-3 Yes
  • 20. 21 Raw Material Case Study MMV Spiked Unprocessed Bulk Bioreactor Material Analyzed Unprocessed Bulk 1ml of Unprocessed Bulk 1TCID50 MMV Spike 1ml of Unprocessed Bulk Spike 1X PBS Sample Purification Sample Purification Bioreactor Target Detected BPV-3 No HPV-4 No MMV Group (All reported 19 MMV Strains) Yes PPV-1 No HBoV No HPV-B19 No PBoV No BHoKo No ChiP No PPV-456 No PPV-23HOKO No BPV-1 No BPV-2 No BPV-3 No Target Detected BPV-3 No HPV-4 No MMV Group (All reported 19 MMV Strains) No PPV-1 No HBoV No HPV-B19 No PBoV No BHoKo No ChiP No PPV-456 No PPV-23HOKO No BPV-1 No BPV-2 No BPV-3 No Results Results
  • 21. • High sensitivity and specificity for detection of Adventitious Agents • Faster molecular test results would provide better control over the manufacturing process • Broad spectrum helps further reduce risk • Can detect both culturable and non-culturable viruses • Earlier results = earlier release of product: months to days/hours: inventory, space, facility utilization • Newer biologics have short shelf life and are not amenable to cryopreservation storage Benefits of degenerate primer methodology Advantages: 22 Disadvantages: • Molecular methods are not able to distinguish between infectious virus vs. “free” DNA/RNA  This risk can be mitigated by screening the starting material upfront. If a virus persists and contaminates your product, then risk has been mitigated by early detection of the virus.
  • 22. Team Acknowledgments Quanyi (Charlie) Li, PhD Teng Vang, MS Audrey Chang, PhD Reginald Clayton, PhD Adam Inche, PhD Colette Cote, PhD Martin Wisher, PhD Karin Heffner, PM 23
  • 23. A poll will now occur